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ABSTRACT

A significant percentage of medications prescribed in the United States are prescribed to elderly
adults, which is due to the increase in chronic illness as Americans age. This increase in the use
of medications amongst the elderly population has led to the issue of polypharmacy, which can
lead to negative patient outcomes. An evidence-based practice pilot project was performed at a
large tertiary care facility in Virginia. The aim of the scholarly project was to integrate three
deprescribing tools into the everyday practice of pharmacists at the facility. Three outcomes were
achieved: (1) Pharmacists understood how to accurately utilize the deprescribing tools in practice
and the elderly populations’ average number of medications decreased on the (2) admission and
(3) discharge medication reconciliations as a result of integrating the deprescribing tools:
START, STOPP, and Beers Criteria. A three-question survey completed by the pharmacy staff
pre- and post-education to determine the efficacy of the intervention. The pharmacy staff’s
knowledge about the deprescribing tools increased related to the START criteria 3.00 to 4.16
(+1.16 mean points), STOPP criteria 3.16 to 4.16 (+1.00 mean points), and the Beers Criteria
4.66 to 4.83 (+0.16 mean points). The average number of medications decreased on admission
from 13.62 to 11.88 (-1.74) and on discharge from 15.1 to 14.14 (-0.96). Providing education to
pharmacists and healthcare providers on the deprescribing tools will help to decrease the
incidence of polypharmacy, ultimately reducing adverse drug reactions and improving patient
outcomes.
Keywords: Polypharmacy, elderly, START/STOPP criteria, Beers Criteria, deprescribing
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SECTION ONE: INTRODUCTION
This scholarly project analyzed current data related to polypharmacy in the elderly
population. This is an important topic due to the growing number of older adults in the United
States of America (U.S.). Since Americans are living longer, healthier lives, the elderly
population has become the fastest-growing population in the U.S. (Healthy People 2020, 2019).
The elderly population makes up around 52 million individuals but is expected to double to
nearly 95 million by the year 2060, with individuals aged 65 and older making up 23% of the
U.S. population (Population Reference Bureau, 2019). With elderly individuals making up such a
large part of the U.S population, issues affecting this demographic should be an important
consideration for a healthcare system.
Polypharmacy, which can be defined as taking more medications than may be medically
necessary or taking five or more medications can cause major problems amongst the elderly
population. According to Tegegn et al. (2019), elderly individuals that engage in polypharmacy
are more likely to have a much lower quality of life than those who do not. Another major
problem with polypharmacy in the elderly population is the increased risks of drug-drug
interactions and adverse drug effects (Sherman, Davis, & Daniels, 2017). According to Gómez et
al. (2015) polypharmacy places elderly individuals at a markedly higher risk of mortality. Lastly,
elderly individuals that take enough medications to be considered polypharmacy are more likely
to have increased cognitive impairments, increased risk for urinary incontinence, and decreased
medication compliance (Maher, Hanlon, & Hajjar, 2014).
Background
Polypharmacy includes taking more medications than may be medically necessary or
taking more than a specified amount of medications. Polypharmacy continues to be a major issue
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within the U.S. One study found that 76.3% of the elderly had a problem with polypharmacy at
one tertiary care facility (Al-Hashar, Al Sinawi, Al Mahrizi, & Al-Hatrushi, 2016). Another
study found that 41.4% of elderly individuals took five-to-eight medications and 37.2% were on
nine or more medications (Maher, Hanlon, & Hajjar, 2014). In addition, Barclay, Frassetto,
Robb, & Mandel (2018), found that 57% of women aged 65 and older in the U.S. took 5 or more
medications daily.
Polypharmacy amongst the elderly population is an important topic that needs to be
explored further for a variety of reasons. One reason is that many elderly individuals live in or
below the poverty level. In fact, around 25 million elderly individuals in the U.S. live at or below
250% of the federal poverty level (National Council on Aging, 2017). Another reason is that
polypharmacy leads to increased adverse effects and drug-drug interactions. More than 175,000
elderly individuals will visit an emergency department in the U.S. for an adverse drug reaction
due to commonly prescribed medications (Sherman, Davis, & Daniels, 2017). There is
significant value to decreasing polypharmacy in the elderly population, which includes lowering
the risk of increased drug-drug interactions and adverse drug effects (Cantlay, Glyn, & Barton,
2016).
Problem Statement
The elderly population in the U.S. comprises a substantial proportion of the individuals
with a high incidence of polypharmacy. For this scholarly project, elderly is defined as
individuals aged 65 years old and older. The definition of polypharmacy varies, but the most
widely accepted definition is an individual taking five or more medications daily (Maher,
Hanlon, & Hajjar, 2014). There does however continue to be disagreement about an exact
number of medications that will definitively define polypharmacy. Polypharmacy is a problem
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for the elderly population for several reasons including being a financial burden, causing
increased falls and injuries, causing adverse drug interactions, and resulting in an increase in
cognitive impairment (Sherman, Davis, & Daniels, 2017).
Purpose of the Project
The aim of this DNP scholarly project was to integrate various deprescribing tools into
the everyday practice of pharmacists that care for elderly patients aged 65 and older. The tools
that were integrated as part of this scholarly project were the Screening Tool to Alert to Right
Treatment (START), the Screening Tool of Older People's Prescriptions (STOPP), and the Beers
Criteria. These tools were integrated to avoid inappropriate medication use in the elderly
population, to ensure that elderly individuals are on the appropriate medications at proper doses,
and to identify and eliminate potentially inappropriate prescribing practices (O'Mahony et al.,
2014). Lastly, this project aimed to decrease potential side effects of polypharmacy through
pharmacist education about polypharmacy prevention tools.
Clinical Question
Will educating the pharmacists that make recommendations to the providers who work
with the elderly population in acute care settings on the appropriate use of the deprescribing tools
START, STOPP, and Beers Criteria decrease the incidence polypharmacy on admission and
discharge?
SECTION TWO: LITERATURE REVIEW
The literature suggests that polypharmacy amongst the elderly population continues to be
a problem. Elder adults are more likely to suffer from polypharmacy due to their increased
number of health issues and chronic diseases (Sherman, Davis, & Daniels, 2017). Elderly
individuals that take enough medications to be considered polypharmacy are more likely to have
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negative side effects from the practice (Maher, Hanlon, & Hajjar, 2014). One study found that
there may be certain predictors of polypharmacy in elderly adults, such as the type and number
of diseases the individual suffers from (Wongpakaran et al., 2018). Another study found that
45% of prescriptions are dispensed to patients older than 65 (Cantlay, Glyn, & Barton, 2016).
According to Sherman et al. (2017), the silo effect, which is the lack of information sharing
between healthcare providers combined with patients utilizing multiple healthcare providers, and
pharmacies have led to an increase in polypharmacy.
Barclay, Frassetto, Robb, & Mandel (2018) found that utilizing tools such as the START,
STOPP, Beers Criteria, and medication reconciliation helps to reduce polypharmacy and its side
effects. One study found that the total number of medications decreased by 11.2% after
reviewing the medication record for potentially inappropriate medications and eliminating them
(Stuhec, Gorenc, & Zelko, 2019). Another study showed that using the STOPP tool decreased
potentially inappropriate medications at discharge by 22% (Urfer, Elzi, Dell-Kuster, & Bassetti,
2016). Additionally, a study concluded that educating providers about the health implications of
polypharmacy may help reduce the incidence of medication-related adverse events, which may
improve treatment outcomes (Al-Hashar, Al Sinawi, Al Mahrizi, & Al-Hatrushi, 2016). There is
an ample amount of evidence in the literature that shows that polypharmacy continues to be a
problem among elder adults. Lastly, the literature also shows that using tools such as the
START, STOPP, and Beers Criteria can reduce the prevalence of polypharmacy in the elderly
population.
Search Strategy
For this DNP scholarly project several search strategies were utilized. First, a general
search of the internet was done to gather information on the various polypharmacy prevention
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tools. This search was done on Bing.com and Google.com using several keywords. These
keywords include polypharmacy prevention, polypharmacy tool, polypharmacy in the elderly,
START and STOPP criteria, and Beers Criteria.
Next, a search was done of the Liberty University nursing and medical science databases;
specifically, the Medline with Full-Text (EBSCO) database was used. The search terms included:
polypharmacy, elderly, aging, elimination, START and STOPP, Screening Tool to Alert Doctors
to Right Treatment, Screening Tool of Older Persons, potentially inappropriate prescriptions, and
Beers Criteria. A Boolean search mode was used, and the search was narrowed in several ways.
One narrowing parameter that was utilized was the date. Only articles that were published
between 2014 and 2019 were searched. This was done to ensure that all information used for the
scholarly project is current. Another narrowing parameter that was used included only searching
peer reviewed articles to help confirm the validity of the information. Lastly, only full text
articles were considered in the search to ensure that the full article contents were available to use.
The original search yielded 346 results. Once the above listed criteria were applied there were
only 84 articles remaining; the first 15 relevant studies were selected for this literature review.
The types of studies that were included in the literature review include descriptive studies, crosssectional studies, retrospective observational studies, and institutional-based quantitative crosssectional surveys.
Critical Appraisal
A table of evidence is provided (Appendix A).
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Synthesis
The literature review that was performed for this scholarly project has yielded a wealth of
information related to polypharmacy in the elderly population. Notably, polypharmacy continues
to be a problem in the elderly population because it has been shown to produce a multitude of
negative side effects such as an increase in cognitive impairments, adverse drug reactions, drugdrug interactions, urinary incontinence, and poor clinical outcomes (Ailabouni, 2016; Cantlay,
2016). Furthermore, evidence shows that the utilization of tools such as the START, STOPP, and
Beers Criteria as a part of clinical decision making has been shown to decrease incidence of
polypharmacy in the elderly population (Ailabouni, 2016; Bordovsky, 2017; Verdoorn, 2015).
Conceptual Framework
The conceptual framework for this project is the Iowa Model of Evidence-based Practice.
Permission was obtained to use the Iowa Model in the DNP scholarly project (Appendix B). The
Iowa Model is a conceptual framework that is a stepwise model to assist the user in
implementing current evidence-based practice at the bedside (Buckwalter et al., 2017). This
model utilizes a step-by-step method that includes seven key steps. These steps include selecting
a topic, forming a team, retrieving evidence, grading evidence, developing an evidence-based
practice standard, implementing the evidence-based practice, and evaluation (Buckwalter et al.,
2017). Topic selection should be based on triggers, such as financial data or process
improvement data (Hall & Roussel, 2016). Once the topic was determined to be a top priority, a
team was formed. It was important that all members of the team had a vested interest in the topic.
Literature must also be available to support the topic, and this support was determined through a
thorough literature review. Related articles were selected utilizing the search criteria, and these
articles were synthesized and critiqued to ensure that there was adequate quality evidence to
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support the topic. Once it was determined that there was enough evidence to support the topic a
pilot study was planned and performed to translate the evidence into practice. This was a
multistep process that included selecting the outcomes to be achieved, collecting baseline data,
finding and interpreting evidence-based practice guidelines, implementing the evidence-based
practice guidelines on the selected pilot units, evaluating the process and outcomes, and
modifying practice guidelines (Hall & Roussel, 2016). Once it was determined that the change in
practice was effective and appropriate, it was instituted into practice. Lastly, the results were
disseminated.
The Iowa Model was applied to this DNP scholarly project. First, the topic was selected:
Preventing Polypharmacy Amongst the Elderly in an Acute Care Setting Through the Integration
of the START, STOPP, and Beers Criteria. Selecting a topic provided a basis for the DNP
scholarly project. The topic selection was based on triggers, with one of the main triggers being a
high incidence of elderly individuals being on many medications that can cause negative side
effects. Next, a team was formed to assist in the planning and implementation of this scholarly
project. A project chair assisted in guiding the graduate student with the DNP scholarly project.
In addition, the unit manager on one of the medical units at the host organization and a
pharmacist at the host organization assisted with the project as members of the team. Evidence
was retrieved through the completion of various scholarly project courses by completing a
thorough literature review. Furthermore, evidence was leveled and graded using the
Melnyk Pyramid (Appendix A). Once the evidence was leveled and graded and was able to
support the DNP scholarly project, it was implemented on the medical units at the host
organization, which took approximately five months to complete. The project involved
implementing an evidence-based practice standard, which included the use of the deprescribing
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tools START, STOPP, and Beers Criteria to decrease polypharmacy on the medical units at the
host organization. Lastly, after the completion of the implementation phase, an evaluation of the
efficacy of the implementation was completed. During the evaluation phase of the DNP scholarly
project the implementation and the outcome of the scholarly project were reviewed (Buckwalter
et al., 2017).
Summary
The literature review has shown a great need for this scholarly project. Notably, the
elderly population continues to deal with polypharmacy and the negative side effects that come
along with it (Maher, Hanlon, & Hajjar, 2014). There are a variety of negative side effects such
as, an increased risk of drug-drug interactions (Sherman, Davis, & Daniels, 2017). Pharmacists
and healthcare providers are at the forefront of change. The literature points to changes that can
be made by pharmacists and healthcare providers using tools such as the deprescribing tools to
prevent potentially inappropriate prescriptions from remaining on the medication reconciliations
of elderly patients (Barclay, Frassetto, Robb, & Mandel, 2018). Furthermore, once potentially
inappropriate prescriptions are minimized, the negative side effects of polypharmacy will be
reduced (Maher et al., 2014).
SECTION THREE: METHODOLOGY
Design
In the research realm the purpose of the DNP is to translate research into practice using
evidence-based practice. Evidence-based practice is the meticulous use of current best evidence
to make the best clinical decisions and improve patient outcomes (Hall & Roussel, 2016). The
DNP scholarly project is an evidence-based practice project. To determine if polypharmacy
amongst the elderly population would be affected by educating pharmacists on the appropriate
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use of the deprescribing tools, an experimental pilot project was performed. The DNP scholarly
project design is discussed in detail in the following sections: Measurable Outcomes, Setting,
Population, Ethical Considerations, Data Collection, Tools, Intervention, and Data Analysis.
The Measurable Outcomes outline the expected outcomes of this scholarly project. The
Setting section describes in detail where the scholarly project took place. The Population section
outlines the focus population that was affected by the scholarly project interventions. The Ethical
Considerations focus on any potential ethical issues that arose during the scholarly project. The
Data Collection section details the method and rationale for all steps of the data collection
process. The Tools section describes all the tools that were used as part of the DNP scholarly
project. The interventions that were used in this project are outlined in the Intervention section of
this proposal. Lastly, the Data Analysis section provides a detailed analysis of the scholarly
projects’ measurable outcomes.
Measurable Outcomes
1. Pharmacists will understand how to effectively utilize deprescribing tools, which include
the START, STOPP, and Beers Criteria.
2. The elderly population’s average number of medications will decrease on the admission
medication reconciliation as a result of implementing the START, STOPP, and Beers
Criteria into practice.
3. The elderly population’s average number of medications will decrease on the discharge
medication reconciliation as a result of implementing the START, STOPP, and Beers
Criteria into practice.
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Setting
The scholarly project pilot took place on the three medical-surgical units at the host
organization. The host organization is a large 612 bed tertiary care facility. The mission at the
host organization is to provide excellent, innovative, and superlative quality care to patients
while providing training to healthcare professionals (Host Organization, 2019). The host
organization uses the acronym ASPIRE for its values, which stands for accountability,
stewardship, professionalism, integrity, respect, and excellence (Host Organization, 2019). The
units were chosen based on the available population. The three units that were selected are
medical-surgical units, but these units care for patients from many other specialties, such as
oncology and cardiac patients. Patients on these medical-surgical units have a variety of
admitting diagnoses, and they come from diverse socioeconomic backgrounds. One of the three
units specializes as a geriatric and palliative care unit. This unit has a population of adult
patients, and a minimum of 60% of those patients are elderly adults aged 65 and older.
The DNP scholarly project aligned directly with the mission and values of the host
organization. Part of the DNP scholarly project involved educating pharmacists who make
medication recommendations to the healthcare providers that work on the pilot units, which
directly aligns with the organization’s mission statement. In addition, reducing cases of
polypharmacy amongst the elderly population promotes the same values as the organization and
the selected units. Furthermore, the organization promotes good stewardship and excellent care
delivery, which directly aligns with the DNP scholarly project.
Population
The population for the DNP scholarly project was elderly adults. All genders, ethnicities,
and races will be included, but only patients that are classified as inpatient during the scholarly
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project timeframe will be considered. At least 100 inpatient admission and discharge medication
reconciliations were reviewed. 50 charts were reviewed prior to the scholarly project intervention
and 50 after the scholarly project intervention was completed. Patient charts were selected using
a purposeful sampling method until the quota was met. Purposeful sampling is ideal for
qualitative research (Etikan, 2016). The second part of the sampling population included the
pharmacists that received education on deprescribing tools. Convenience sampling was used to
select individuals that were educated about the deprescribing tools. Lastly, an appropriate sample
size was needed to ensure validity of the scholarly project; thus, 100 charts were used.
Ethical Considerations
There were a variety of ethical considerations when the scholarly project was implemented.
One ethical consideration was that no harm should be done to the study participants. When
implementing this scholarly project, medication deprescribing was a major part of the process. To
ensure that no harm was done to the patients that participated in this scholarly project, all final
decisions regarding prescribing and deprescribing practices were made by pharmacists and
licensed healthcare providers. Maintaining privacy was another ethical consideration. It was
imperative that privacy was maintained not only for the patients that were part of the scholarly
project, but for the pharmacists and providers that participated in the scholarly project. No names
or other patient identifiers were used in the documentation of the scholarly project data, which
helped to prevent any violation of patient privacy. This graduate student and the project chair
completed research ethics training prior to the planning and implementation of the DNP scholarly
project to ensure protection of human subjects (Appendix C). Approval by Liberty University’s
Institutional Review Board (IRB) (Appendix D) was obtained prior to implementation of the pilot
project. Furthermore, approval by the host organization’s IRB (Appendix E) was also obtained
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prior to the implementation of the pilot project. Approval of the DNP scholarly project by the two
IRB’s showed that the scholarly project had a negligible chance of causing harm to the study
participants.
Data Collection
A two-step data collection process was used for this scholarly project. First, baseline
knowledge was assessed from the pharmacists. This was done by administering a short three
question survey before and after the pharmacist education was provided. This data was collected
by the graduate student heading this scholarly project. The next step in the data collection process
was a chart review, which took place prior to the pharmacist education to evaluate the average
number of medications the elderly patients had on their admission and discharge medication
reconciliation and again after the education was provided. The chart review was completed by the
graduate student. Extraction of data from electronic health records is ideal when the researcher
needs to evaluate data that is relevant to clinical outcomes (Moran, Burson, & Conrad, 2014). A
chart review was the best way to collect data on the average number of medications on the
medication reconciliation, as it provided the researcher with reliable, factual data.
Tools
One of the tools that was used for this project was a survey (appendix G). No permission
was needed to use this survey, as it was created by the graduate student. This survey was used to
collect data from the pharmacists prior to the education and after the education had occurred. The
survey asked a variety of questions that were rated on a 5-point summative scale. Using a
summative scale allowed the researcher to obtain a more exact determination of a person’s attitude
toward a topic (Johnson, 2014). There were several tools used in this scholarly project. These tools
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included the START, STOPP, and Beers Criteria. These tools were used because they are geared
toward evidence-based medication management in the elderly population.
The START tool is used to determine if elderly adults are on the appropriate medications.
This tool takes a wide variety of factors into consideration. Some of these factors include current
guidelines and evidence-based practice criteria (O'Mahony et al., 2014).
The STOPP criteria is a tool that is used to determine the need to deprescribe medication
for elderly adults. This tool takes one main factor into consideration: adverse drug reactions, as
adverse drug reactions are an integral part of poor clinical outcomes amongst the elderly
population. The STOPP criteria also takes current guidelines and evidence-based practice criteria
into account (O'Mahony et al., 2014).
The Beers Criteria is last tool that was used in this scholarly project. The Beers Criteria is
a list of medications that should not be used or should only be used with caution in the elderly
population. These criteria are based on current guidelines, evidence-based practice, and weighing
the risk-benefit profile (Steinman & Fick, 2019). Ultimately, the provider should use their clinical
judgement in conjunction with the deprescribing tools to make the prescribing and deprescribing
decisions.
Intervention
This scholarly project started with the project development phase. This phase involved
writing a detailed scholarly project proposal that included a step-by-step outline of the complete
scholarly project. Then, a letter of support (Appendix F) for the project was secured from the host
organization in support of the scholarly project to be completed within their organization. Next,
the scholarly project went through a 2-step IRB approval process. First, the IRB at Liberty
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University reviewed the scholarly project for approval. Then, the host organization also reviewed
the scholarly project for approval. This 2-step process is in place to ensure that the scholarly project
is ethically responsible and does not violate any human rights (Liberty University, 2019).
The next step was to elicit participants for the scholarly project. To do this an email invite
was sent to perform the educational intervention to the chief of the pharmacy department. The
education session was led by this graduate student via a virtual Microsoft Teams meeting. A brief
description of the scholarly project was discussed with the pharmacists. Then, a short education
session took place to educate the pharmacists on what the deprescribing tools are and on how to
use the deprescribing tools, START, STOPP, and the Beers Criteria. The education also included
the current updates to the tools. A brief three question survey was given to assess the baseline
knowledge of the pharmacists related to the deprescribing tools. An identical three question survey
was given to assess the efficacy of the pharmacist education provided by the graduate student.
A chart review was completed on a total of 100 charts to determine the average number of
medications elderly patients are on at admission and at discharge. A chart review of 50 charts was
completed on admission and discharge medication reconciliations on the pilot units for patients
that were admitted and discharged prior to the pharmacist education. Another chart review of 50
charts was completed on admission and discharge medication reconciliations on the pilot units for
patients that were admitted and discharged after to the pharmacist education was completed.
Biographical data was also collected. This data included, age, gender, insurance status, medication
names, medication dosages, comorbidities, length of stay, medical team, and admission diagnosis.
Outcome evaluation was completed once the scholarly project interventions were
completed and data collection was done. Data analysis of the scholarly project outcomes was
completed by utilizing Fisher’s test. Fisher’s test was utilized due to the small amount of
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information that was analyzed. Once the statistical analysis was completed, the project was sent to
the editor to be edited prior to the project defense. After the scholarly project was edited by the
professional editor the scholarly project chair evaluated the scholarly project for the final approval
to move forward to the project defense. Once the scholarly project got final approval by the project
chair, a project defense was scheduled and completed. After the scholarly project defense was
completed, the project moved forward with preliminary publishing with Liberty University’s
Scholar’s Crossing. Any needed changes were made to the scholarly project as deemed necessary
by Scholar’s Crossing and the scholarly project was published once final approval was granted.
This project was undertaken as a Quality Improvement/Evidence-Based Practice Initiative at the
host organization, and as such was not formally supervised by the Liberty University Institutional
Review Board.
Timeline
The DNP scholarly project was implemented on January 20, 2020. The scholarly project
implementation was completed on June 28, 2020. At this point data analysis began. Data analysis
and interpretation was completed on July 6, 2020. The final defense of the scholarly project was
completed on July 22, 2020. The scholarly project was submitted to the Scholar’s Crossing on July
23, 2020.
Feasibility Analysis
This project is highly feasible, as the host organization is a teaching hospital that
embraces research and learning. Several factors that were discussed: necessary resources,
personnel, technology, budgeting, and a financial analysis. There were several resources that
were necessary to complete the scholarly project. One resource is the paper and printer materials
needed to produce the surveys. Another resource was access to the host organization’s email to
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send requests and notifications to the pharmacy staff that participated in the DNP scholarly
project. Access to the host organization’s electronic health record was also necessary to review
admission and discharge medication reconciliations.
Several personnel members were also needed to complete the scholarly project. First, the
project chair acted as an advisor to guide the graduate student through the DNP scholarly project
process. At the host organization, the group of pharmacists that participated in the DNP scholarly
project were responsible for reviewing the admission, visit, and discharge medication
reconciliations and making prescribing and deprescribing recommendations to the healthcare
providers that cared for the geriatric patients on the pilot units. There was a limited budget
(Appendix H) for this scholarly project. The budget included money to print materials such as
surveys. Additionally, the budget included editing and publishing costs that were needed.
Data Analysis
A detailed data analysis was performed for each of the three measurable outcomes. The
statistical analysis of each measurable outcome was performed using the statistics software
SPSS. The SPSS software allows the researcher to input research data, analyze, and organize the
data in several ways (IBM, n.d.). The SPSS software was used to analyze the pre- and postsurvey data that was obtained from the pharmacist education intervention. This was done to
determine the efficacy of the education the graduate student provided about the deprescribing
tools, START, STOPP, and Beers Criteria. The average number of medications was calculated
for the pre- and post-education chart reviews on the admission and discharge medication
reconciliations. The average number of medications were analyzed to determine if providing
education to the pharmacy staff would decrease the average number of medications the elderly
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population were prescribed on the admission and discharge medication reconciliations posteducation.
SECTION FOUR: RESULTS
A total of 100 charts were reviewed to obtain the average number of medications, preand post-education. Medication and demographic data were collected from the charts. 50 patient
charts were reviewed prior to the pharmacist education. The mean age of the patients was 76.8
years old. The minimum age was 65 and the maximum age was 98 with a standard deviation of
9.152. All 50 patients were insured. 86% of the patients were Caucasian and 14% of the patients
were African American. 38% of the patients were male and 62% were female. The mean length
of stay in the hospital was 4.8 days with a standard deviation of 4.204. 50 patient charts were
reviewed after the pharmacist education was completed. The mean age of the patients was 75.9
years old. The minimum age was 65 and the maximum age was 95 with a standard deviation of
8.386. 98% of the patients were insured. 80% of the patients were Caucasian, 16% of the patients
were African American, and 4% of the patients were Hispanic. 48% of the patients were male
and 52% were female. The mean length of stay in the hospital was 8.6 days with a standard
deviation of 12.142. See the tables 1-4 below for statistical data related to age, length of stay,
gender, and race.
Table 1
Age
Variable

N

Min/Max

Mean Std. Deviation

Pre-Education Age

50

65/98

76.80 9.152

Post-Education Age

50

65/94

75.92 8.386

Note: N- denotes the number of participants
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Table 2
Length of Stay (LOS)
Variable

N

Mean

Min/Max

Range

Std. Deviation

Pre-Education LOS

50

4.80

1/19

18

4.204

Post-Education LOS

50

8.64

1/65

64

12.142

Note: N- denotes the number of participants

Table 3
Gender
Pre-Education Gender (in percentages)
Variable

N

%

Male

19

38%

Female

31

62%

Post-Education Gender (in percentages)
Variable

N

%

Male

24

48%

Female

26

52%

Note: N- denotes the number of participants
Table 4
Race
Pre-Education Race

(in percentages)

Variable

N

%

Caucasian

43

86%

Black

7

14%

Post-Education Race (in percentages)
Variable

N

%

Caucasian

40

80%
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Black

8

16%

Hispanic

2

4%
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Note: N- denotes the number of participants
Descriptive Statistics
All measurable outcomes were achieved during the implementation of the DNP scholarly
project. The pharmacists gained a greater understanding of the deprescribing tools, START,
STOPP, and Beers Criteria. This was determined by surveying the pharmacy staff with a preand post-education questionnaire that used a 5-point summative scale. There was an increase in
the mean on question 1 from 3.00 to 4.16 (+1.16), question 2 from 3.16 to 4.16 (+1.00), and
question 3 from 4.66 to 4.83 (+0.16). In addition, the average number of medications decreased
after the pharmacist education was performed for the admission medication reconciliation that
went from an average of 13.62 before the pharmacist education was completed to 11.88 after the
pharmacist education was completed, a difference of -1.74. Furthermore, the average number of
medications decreased after the pharmacist education was performed for the discharge
medication reconciliation that went from an average of 15.10 before the pharmacist education
was completed to 14.14 after the pharmacist education was completed, a difference of -0.96.
Measurable Outcome 1
The pharmacists gained a better understanding on how to effectively utilize the
deprescribing tools, which include the START, STOPP, and Beers Criteria. The results reflected
a normal distribution (Appendix K). This was exemplified using a Kolmogorov-Smirnov test (KS test) to test the assumption. Furthermore, the education given to the pharmacists increased their
base of knowledge, thus allowing them to better manage the medication reconciliations of the
elderly population on the pilot units.
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Table 5
Survey Question 1
Pre: How familiar are you with utilizing the START Tool?
Descriptive

Statistic

Mean

3.0000

Median

3.0000

Std. Deviation

1.89737

Min/Max

1.00/5.00

Range

4.00

Post: How familiar are you with utilizing the START Tool?
Descriptive

Statistic

Mean

4.1667

Median

4.0000

Std. Deviation

.75277

Min/Max

3.00/5.00

Range

2.00

Table 6
Survey Question 2
Pre: How familiar are you with utilizing the STOPP Tool?
Descriptive

Statistic

Mean

3.1667

Median

3.5000

Std. Deviation

1.83485

Min/Max

1.00/5.00

Range

4.00

Post: How familiar are you with utilizing the STOPP Tool?
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Descriptive

Statistic

Mean

4.1667

Median

4.0000

Std. Deviation

.75277

Min/Max

3.00/5.00

Range

2.00

Table 7
Survey Question 3
Pre: How familiar are you with utilizing the Beers Criteria?
Descriptive

Statistic

Mean

4.6667

Median

5.0000

Std. Deviation

.51640

Min/Max

4.00/5.00

Range

1.00

Post: How familiar are you with utilizing the Beers Criteria?
Descriptive

Statistic

Mean

4.8333

Median

5.0000

Std. Deviation

.40825

Min/Max

4.00/5.00

Range

1.00
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Measurable Outcome 2
The elderly population’s average number of medications decreased on the admission
medication reconciliation as a result of implementing the START, STOPP, and Beers Criteria.
Utilizing the deprescribing tools had an impact on the average number of medications on the
admission medication reconciliation, which had a normal distribution. The distribution was
tested using the K-S test with a statistic of .120 and a significance of .067 for the pre-education
admission data and a statistic of .131 and a significance of .031 post- education admission data
(Table 8). The K-S test is a goodness-of-fit test that compares observed data to the quantiles of
normal distribution (Sullivan, 2017).
Measurable Outcome 3
The elderly population’s average number of medications will decrease on the discharge
medication reconciliation because of implementing the START, STOPP, and Beers Criteria. The
results of Measurable Outcome 3 had a normal distribution. Measurable Outcome 3 also utilized
the K-S test to determine that results yielded a normal distribution. The distribution was tested
using the K-S test with a statistic of .127 and a significance of .043 for the pre-education
discharge data and a statistic of .080 and a significance of .200 post- education discharge data
(Table 8).
Table 8
K-S Test
Variable

Statistic

df

Sig.

Pre-Education Admission

.120

50

.067

Post-Education Admission

.131

50

.031

Pre-Education Discharge

.127

50

.043

Post-Education Discharge

.080

50

.200*
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*This is a lower bound of the true significance
df- degrees of freedom
SECTION FIVE: DISCUSSION
Implication for Practice
Combating polypharmacy has immense clinical significance. Polypharmacy continues to
be a problem as the literature has shown. Many elderly adults are on a substantial number of
medications for several reasons, most notably, an increased number of chronic diseases
(Sherman, Davis, & Daniels, 2017). Polypharmacy causes many adverse reactions in the elderly
(Cantlay, Glyn, & Barton, 2016). These adverse reactions are responsible for problems like
increased hospitalizations (Tegegn et al., 2019). The literature and the DNP scholarly project
results have shown that it is important to continue to educate pharmacists and healthcare
providers on current evidence-based practice tools, such as the START, STOPP, and Beer’s
Criteria. These tools help pharmacists and healthcare providers to make better clinical decisions;
thus, decreasing the number of potentially harmful medications elderly individuals are taking
(O’Mahony, 2019). The DNP scholarly project has reflected an increase in knowledge of the
pharmacy staff related to the deprescribing tools following the education intervention.
Furthermore, the results of the project showed a decrease in the average number of medications
the elderly population was taking following the pharmacist education. The polypharmacy
reduction project has contributed to clinical practice not only by helping to decrease unnecessary
medications, but by increasing the knowledge of the pharmacists at the host organization that
help to care for elderly patients. The DNP scholarly project has shown the host organization that
polypharmacy is indeed a problem and that there is a need to continue to provide education on
the deprescribing tools and updates as they become available. Decreasing polypharmacy will
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also 0benefit individual organizations by reducing costs, but it will benefit society (Johansson et
al., 2016).
The DNP scholarly project findings did show that the pharmacy staff had an increase in
knowledge following the education intervention. A possible alternative explanation for this
finding is that the small survey response size may have skewed the results. The results will need
to be replicated with a larger sample size to add further validity to the results. The DNP scholarly
project results showed a decrease in the average number of medications on the admission and
discharge medication reconciliations. A possible alternative explanation for these results is that
each case is different based on the individual’s medical history and provider preferences to
prescribing and deprescribing. Additional validity may be granted if the results of the pilot
project were replicated.
There are several project limitations that were determined during the implementation of
the DNP scholarly project. One limitation is the response size for the pharmacist population.
Only six pharmacists responded to the pre- and post-education survey. A larger sample would
have added to the validity of the results (Mateo & Foreman, 2014). Another limitation that was
identified is that the COVID-19 pandemic was peaking during the months that the project
implementation was occurring. This limitation may have affected the available population during
the data collection period. The pilot project also had a time limitation. The DNP scholarly project
had to be completed during the time the graduate student was in graduate school. A potential bias
in this pilot project is that the data for the project was collected by the graduate student on
medical units in which the graduate student researcher is employed.
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Sustainability
The DNP scholarly project intervention and implementation is a sustainable practice
change. The results of the scholarly project have shown that the intervention is effective at
helping to reduce polypharmacy amongst the elderly population in an acute care setting. The
literature and the DNP scholarly project have shown that there is a need to provide education to
pharmacists and healthcare providers (Al-Hashar et al., 2016). With continued, on-going
education of pharmacists and healthcare providers, the results can be sustained within the
organization. It is feasible to keep the practice change going, as it will not be costly to the
healthcare system. The current healthcare environment has shown that a need to reduce costs
when possible and reducing polypharmacy can help to reduce those healthcare costs by reducing
unnecessary hospitalizations from adverse effects of polypharmacy (Johansson et al., 2016).
Dissemination Plan
Once the DNP scholarly project is completed, the graduate student plans to submit the
scholarly project to Liberty University’s Scholar’s Crossing for future publication. In addition,
the graduate student will submit a professional manuscript to the Journal of the American
Geriatrics Society (JAGS) for publication. The JAGS is a journal that specializes in research,
geriatric education, and clinical practice, public policy related to the geriatric population, in
addition to creating the Beers Criteria (American Geriatrics Society, 2020) The manuscript will
be written in accordance with the journal’s submission requirements. The DNP scholarly project
was presented at Liberty University’s 2020 Research Week. A poster presentation and an oral
presentation were digitally presented and published in Liberty University’s Scholar’s Crossing.
The graduate student plans to submit an abstract to present a poster presentation at the 2021
American Association of Nurse Practitioner’s National Conference.
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Appendix A: Evidence Table

Name: Preventing Polypharmacy Amongst the Elderly in an Acute Care Setting Through the Integration of the START,
STOPP, and Beers Criteria
Clinical Question: Will educating pharmacists that make recommendations to healthcare providers that work with the elderly
population in acute care settings on the appropriate use of the deprescribing tools, START, STOPP, and Beers Criteria
decrease the incidence polypharmacy on admission and discharge?

Article Title, Author, etc.

Ailabouni, N., Nishtala, P., &
Tordoff, J. (2016).
Examining potentially
inappropriate prescribing
in residential care using
the STOPP/START
criteria. European
Geriatric Medicine, 7(1),
40-46.
doi:10.1016/j.eurger.2015
.11.004

Study
Purpose

Identify the
prevalence of
potentially
inappropriate
prescriptions
and potential
prescribing
omissions in
older adults

Sample

Methods

The
population
used for
this study
included
individuals
aged 65
and older
that live in
a
residential
care home

Nonexperimen
tal,
univariate
regression
analysis

Study
Results

The results
of this study
showed that
there were
205
potentially
inappropriate
prescriptions
among 102
residents and
66 potential
prescribing

LOE

Level 4:
correlatio
nal
design

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

Small
sample size
and
performed
in 2 small
facilities, an
older
version of
the
START/ST
OPP criteria
was used,

Yes, this
study uses
several
credible
tools that
can be
utilized in
other setting
amongst
elderly
patients.
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Article Title, Author, etc.

Bordovsky, S., Il’ina, E.,
Nikulin, V.,
Gorbatenkova, S.,
Bogova, O., & Sychev, D.
(2017). Frequency of
potentially inappropriate
prescribing of the
medications in senile
patients according to
STOPP/START criteria.
Clinical Therapeutics,
39(8), e46.
doi:10.1016/j.clinthera.20
17.05.143

41

Study
Purpose

The study
aimed to
analyze the
frequency of
potentially
inappropriate
prescribing of
the
medications
in senile
patients
according to
STOPP/STA
RT criteria.

Sample

Methods

Study
Results

in New
Zealand.

omissions
among 49
residents.

The
Literature
sample for review
this study
included
the case
history
records of
170
individuals
aged 65
and older
who were
under the
treatment
of the
cardiology
departmen
t taking an

Utilizing the
STOPP/STA
RT criteria
135 IPs were
detected in
the
patient’s case
history
records,
which makes
8.698% of
the overall
prescriptions

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

and Data
were
collected
and
interpreted
systematical
ly by one
investigator.
Level 5:
systemati
c review
of
descriptiv
e&
qualitativ
e studies

One
limitation of
this study
includes
referring to
the patient
age group
as “senile
age”
Another
limitation of
this study is
that there
was a small
sample used
and it only
focused on

Yes, this
study
provides a
solid focus
on how to
use the
STOPP/ST
ART
criteria with
cardiology
medications
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Study
Purpose

Sample

Methods

Study
Results

LOE

average of
8.810
medication
s

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

cardiology
patients.

Da Costa, F. A., Periquito, C.,
Carneiro, M. C.,
Oliveira, P.,
Fernandes, A. I., &
Cavaco-Silva, P. (2016).
Potentially inappropriate
medications in a sample
of Portuguese nursing
home residents: Does the
choice of screening tools
matter? International
Journal of Clinical
Pharmacy, 38(5), 11031111.
doi:10.1007/s11096-0160337-y

This study
aims to detect
the
prevalence of
potentially
inappropriate
medications
and potential
prescribing
omissions in
a sample of
Portuguese
nursing
homes
residents

The
sample
includes
161
individuals
aged 65
and older
that reside
in one of
four
Portuguese
nursing
home.

Descriptiv
e crosssectional
study

807
potentially
inappropriate
medication
and 90
potential
prescribing
omissions
were
identified
through the
application
of the
START,
STOPP, and
Beers criteria

Level 4:
correlatio
nal
design

Small
sample size

Yes, this
study
utilizes the
three major
tools used
to decrease
polypharma
cy in the
elderly
population
and
provides a
comparison
of each.

Komagamine, J., Sugawara, K., &
Hagane, K. (2018).
Characteristics of elderly
patients with

The purpose
of this study
was to
evaluate the

A sample
of 136
patients
aged 65

Retrospect
ive cross-

Of the 136
patients in
the study, 82
patients

Level 2:
quasiexperime

There were
several
limitations
to this

Yes, this
study looks
at a
different
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Article Title, Author, etc.

polypharmacy who refuse
to participate in an inhospital deprescribing
intervention: a
retrospective crosssectional study. BMC
Geriatrics, 18(1), 96.
doi:10.1186/s12877-0180788-1
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Study
Purpose

prevalence of
potentially
inappropriate
medication
use in elderly
patients
accepting and
refusing a
deprescribing
intervention
and to
investigate
factors
associated

Sample

and older
with at
least 5
medication
s upon
admission
to the
orthopedic
unit

Methods

sectional
study

Study
Results

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

participated
in
deprescribing
and 54
declined the
intervention

ntal
design

study:
Small
sample size,
one center
was used,
over-thecounter
medication
were
excluded

side of
polypharma
cy amongst
the elderly,
refusing to
deprescribe

Between
2005-2010
polypharmac
y increased
amongst the
elderly
population.

Level 6:
descriptiv
e design

No
limitations
were
mentioned
in this study

Yes, this
study
focuses on
the
magnitude
of

with
deprescribing
refusal
Article 5 Markovic-Pekovic, V.,
& Skrbic, R. (2016).
Long-term drug use and
polypharmacy among the
elderly population in the
Republic of Srpska,
Bosnia and Herzegovina.

To analyze
the long-term
drug use and
the
prevalence of
polypharmac
y

The
Retrospect
sample
ive study
size is 1.4
million
individuals
, but the
study only
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Article Title, Author, etc.

Vojnosanitetski pregled,
73(5), 435-441.
doi:10.2298/vsp15022403
2m

Noale, M., Veronese, N., Cavallo
Perin, P., Pilotto, A.,
Tiengo, A., Crepaldi, G.,
& Maggi, S. (2015).
Polypharmacy in elderly
patients with type 2
diabetes receiving oral
antidiabetic treatment.
Acta Diabetologica,
53(2), 323-330.
doi:10.1007/s00592-0150790-4

44

Study
Purpose

Sample

among the
elderly
population

focused on
the
individuals
that were
at least 65
years old

Identify the
characteristic
s associated
with
polypharmac
y in a cohort
of elderly
diabetic
patients being
treated with
oral
hypoglycemi
c agents

The
sample
includes
1342
diabetic
patients
that were
enrolled I
a diabetic
center and
participate
d in a
metabolic
study, are
aged 65
and older,
have type
2 diabetes,
and are on
oral

Methods

Study
Results

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

The increase
was greater
in women

Crosssectional
survey,
longitudin
ally
designed

57.1% of the
study
participants
were found
to have
polypharmac
y; females
were found
to have more
issues with
polypharmac
y; patient’s
with
polypharmac
y had higher
rates of
malnutrition

polypharma
cy

Level 6:
descriptiv
e design

The sample
may be
biased due
to using
patients at a
diabetic
center who
are
inherently
more
complex
than those
that do not.
Insulin
patients
were
excluded.

Yes, this
can help to
show the
magnitude
of
polypharma
cy amongst
diabetic
patients
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Study
Purpose

Sample

Methods

Study
Results

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

antidiabeti
c
medication
Ozlek, E. (2019). Rationale,
design, and methodology
of the EPIC
(Epidemiology of
Polypharmacy and
potential drug-drug
Interactions in elderly
Cardiac outpatients)
study. Turk Kardiyoloji
Dernegi Arsivi-Archives
of the Turkish Society of
Cardiology, 47(5), 391–
398.
doi:10.5543/tkda.2019.27
724

Determine
the
prevalence of
polypharmac
y,
inappropriate
drug use, and
drug-drug
interactions
amongst
elderly
cardiology
outpatients

NonNonProbability interventio
Sample:
nal study
approxima
tely 5000
patients,
aged 65
and older

The Charlson
comorbidity
index will
divide
patients into
3 groups.
Polypharmac
y will be
defined as 5
or more
medication,
and drugdrug
interactions
will be
checked in
Lexicomp.

Level 6:
descriptiv
e design

The study is
not
complete
until
8/30/19;
will followup with
results

Yes, once
complete
this will
provide a
large-scale
study on the
prevalence
of
polypharma
cy and
drug-drug
interactions

Stuhec, M., Gorenc, K., &
Zelko, E. (2019).
Evaluation of a
collaborative care
approach between general

Determine
whether a
clinical
pharmacists
medication

91 patients
aged 65
and older
that are on
10 or more

Clinical
pharmacist
recommende
d 625
interventions

Level 4:
correlatio
nal
design

No control
groups. No
humanistic
or clinical

Yes, this
study
provides a
foundation
to analyze

Retrospect
ive
observatio
nal
medical
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Study
Purpose

Sample

Methods

Study
Results

practitioners and clinical
pharmacists in primary
care community settings
in elderly patients on
polypharmacy in
Slovenia: A cohort
retrospective study
reveals positive evidence
for implementation. BMC
Health Services Research,
19(1), 118.
doi:10.1186/s12913-0193942-3

review
service can
improve the
quality of
drug
prescribing in
elderly
patients
treated with
polypharmac
y in primary
care

medication
s

chart
review
study

and general
practitioner
accepted
304. A
significant
amount of
medications
was
decreased
after
following the
pharmacists’
recommendat
ions

Tegegn, H. G., Erku, D. A.,
Sebsibe, G., Gizaw, B.,
Seifu, D., Tigabe, M., …
Ayele, A. A. (2019).
Medication-related
quality of life among
Ethiopian elderly patients
with polypharmacy: A
cross-sectional study in an
Ethiopia university
hospital. PLOS ONE,
14(3), e0214191. doi:

The purpose
of this study
is to assess
the
medicationrelated
quality of life
among older
patients with
polypharmac
y

Sample of
150 elder
patients
that visited
an internal
medicine
ward that
have a
mean age
of 70 years
old

Institution
al-based
quantitativ
e crosssectional
survey

Poor quality
of life was
reported in
75% of the
participants.
Frequency of
hospital
visits and
medication
number
showed a
statistical

LOE

Level 4:
correlatio
nal
design

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

outcome
measure

type-X
drug-drug
interactions

Crosscultural
validity,
reliability,
and
psychometri
c property
of the
Amharic
version of
MRQoL
have not

Yes, this
study looks
at quality of
life related
to
polypharma
cy, which
will be an
important
aspect of
the
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Study
Purpose

Sample

Methods

10.1371/journal.pone.021
4191

Verdoorn, S., Kwint, H.-F., Faber, A.,
Gussekloo, J., & Bouvy, M. L. (2015).
Majority of drug-related problems
identified during medication review are
not associated with STOPP/START
criteria. European Journal of Clinical
Pharmacology, 71(10), 1255–1262.
https://doiorg.ezproxy.liberty.edu/10.1007/s00228015-1908-x

Assignment 2

Study
Results

LOE

positive
association
with the
likelihood of
severe
impairment
Determine to
what extent
STOPP/STA
RT
correspondin
g to drugrelated
problems

13 Dutch
communit
y
pharmacie
s, 457
communit
y-dwelling
patients
aged 65
and older
that use 5
or more
medication
s

Nonexperimen
tal,
descriptive
survey

81% of drugrelated
problems
were not
related to the
use of
START/STO
PP criteria.

Level 4:
correlatio
nal
design

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

been done.
Polypharma
cy exposure
time was
not
analyzed.

scholarly
project

A modified
START/ST
OPP criteria
was used.
Medication
omissions
could not be
measured.
Pharmacists
were not
properly
trained in
the use of
START/ST
OPP
criteria.

No, this
study
cannot be
generalized
to
polypharma
cy in acute
or primary
care.
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Study
Purpose

Sample

Methods

Study
Results

LOE

Gómez, C., Vega-Quiroga, S., BermejoPareja, F., Medrano, M. J., Louis, E. D.,
& Benito-León, J. (2015). Polypharmacy
in the elderly: A marker of increased risk
of mortality in a population-based
prospective study. Gerontology, 61(4),
301–309. https://doiorg.ezproxy.liberty.edu/10.1159/0003653
28

The purpose
of this study
is to
determine in
a populationbased study
whether
polypharmac
y is
associated
with
increased risk
of mortality
in elderly
persons.

The
sample
includes
5,052
people
aged 65
years and
older

Longitudin
al
population
-based
prospectiv
e study.

Around half
of the study
participants
died prior to
the follow-up
period,
which
indicated that
polypharmac
y amongst
the elderly
population
puts them at
increased
risk of
mortality.

Level 4:
correlatio
nal study

Leiss, W., Méan, M., Limacher, A.,
Righini, M., Jaeger, K., Beer, H.-J., …
Aujesky, D. (2015). Polypharmacy is
associated with an increased risk of
bleeding in elderly patients with venous
thromboembolism. Journal of General
Internal Medicine, 30(1), 17–24.
https://doi-

The purpose
of the study is
to examine
whether
polypharmac
y increases
the risk of
bleeding
amongst the

The cohort
sample
was 830
patients
aged 65
years old
and older

Prospectiv
e cohort
study

49.8% of the
patients had
polypharmac
y. The mean
follow-up
duration was
17.8 months.
This study
found that

Level 4;
correlatio
nal
design

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

This study
does not
consider
that
communitydwelling
elders may
take selfprescribed
medication
and
alternative
medication
that they do
not tell the
provider
about.

Yes,
provides
foundationa
l
information
related to
the
increased
risk of
mortality
associated
with
polypharma
cy amongst
the elderly
population.
Yes, this
study
provides
foundationa
l
information
related to a
risk of
major
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Study
Purpose

Sample

org.ezproxy.liberty.edu/10.1007/s11606014-2993-8

elderly
population
that receive
vitamin K
antagonists
for acute
venous
thromboembo
lism (VTE).

that have a
VTE.

Strabner, C., Frick, E., Stotz-Ingenlath,
G., Buhlinger-Göpfarth, N., Szecsenyi, J.,
Krisam, J., … Joos, S. (2019). Holistic
care program for elderly patients to
integrate spiritual needs, social activity,
and self-care into disease management in
primary care: study protocol for a clusterrandomized trial. Trials, 20(1), 364.

The purpose
of this study
is to
determine
whether
combining
disease
management

360
Patients
aged
70 years
old or
older with
at least
three

Methods

Study
Results

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

patients with
polypharmac
y had a
significantly
higher
incidence of
major
bleeding and
clinically
relevant nonmajor
bleeding in
elderly
patients
receiving
vitamin K
antagonists
for VTE.
Explorativ
e, clusterrandomize
d
controlled
trial with
general
practices

It is
hypothesized
that by
incorporating
holistic care,
the elderly
persons

bleeding
due to
polypharma
cy in the
elderly
population

Level 2;
randomiz
ed
controlle
d trial

There is a
lack of
generalizabi
lity to this
study.
There is not

No, even
once this
study is co
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Study
Purpose

Sample

Methods

Study
Results

https://doiorg.ezproxy.liberty.edu/10.1186/s13063019-3435-z

programs
with
interventions
to address
these
dimensions is
feasible and
has any
impact on
relevant
outcomes in
elderly
patients with
polypharmac
y

chronic
conditions
receiving
at least
three
medication
s
participati
ng in at
least one
disease
manageme
nt program

as the unit
of
randomiza
tion will
be
conducted
and
accompani
ed by a
process
evaluation

quality of life
will improve.

Urfer, M., Elzi, L., Dell-Kuster, S., &
Bassetti, S. (2016). Intervention to
improve appropriate prescribing and
reduce polypharmacy in elderly patients
admitted to an internal medicine unit.
Plos One, 11(11), e0166359. https://doiorg.ezproxy.liberty.edu/10.1371/journal.p
one.0166359

The purpose
of this study
is to test the
efficacy of an
easy-to-use
checklist
aimed at
supporting
the
therapeutic
reasoning of

900
patients
aged 65
years old
and older,
half have
been
hospitalize
d before
the
introductio

Singlecenter,
interventio
nal, quasiexperimen
tal beforeafter study

After the
implementati
on of the
checklist,
there was a
significant
reduction in
the
prescribing
of potentially
inappropriate

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

a random
selection

Level 3:
quasiexperime
ntal
design

Randomizat
ion was not
possible
because of
the
contaminati
on effect

Yes, the
study
provides a
tool that
may be
generalized
to the
scholarly
project to
decrease the
prescribing
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Wongpakaran, N., Wongpakaran, T.,
Sirirak, T., Jenraumjit, R., Jiraniramai, S.,
& Lerttrakarnnon, P. (2018). Predictors of
polypharmacy among elderly Thais with
depressive and anxiety disorders:
Findings from the DAS study. BMC
Geriatrics, 18(1), 309. https://doiorg.ezproxy.liberty.edu/10.1186/s12877018-1001-2
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Study
Purpose

Sample

physicians to
reduce
inappropriate
prescribing
and
polypharmac
y

n of the
checklist
and the
other half
after.

The purpose
of this study
is to
investigate
potential
predictive
psychosocial
factors
related to
polypharmac
y in elderly
Thai people

803
patients
participate
d in this
study and
67.6% of
the
patients
were aged
65 years
old and
older.

Methods

Study
Results

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

medications
amongst the
participants

Proportion
al odds
logistic
regression

The results
Level 6:
of the study
descriptiv
list how
e design
many
medications,
the type of
medications,
and the
various
comorbiditie
s. The study
found that
individuals
with an
anxiety
disorder were
4 times more
likely to have
higher

of
potentially
inappropriat
e
medications

One
limitation is
that the
medical aid
status of the
participant
was not
recorded.

Yes, this
study
provides a
foundation
to organize
data to the
scholarly
project. The
study lists
various
important
data about
the types of
medication
the patients
are on and
the
comorbiditi
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Study
Purpose

Sample

Methods

Study
Results

polypharmac
y and those
with
dyslipidemia
were likely
to have lower
incidence of
polypharmac
y.

LOE

Would Use
as
Study
Evidence to
Limitations
Support a
Change?

es that they
have
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Appendix B: Iowa Model Permission Letter

You have permission, as requested today, to review and/or reproduce The Iowa Model Revised: Evidence-Based Practice
to Promote Excellence in Health Care. Click the link below to open.

The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health Care

Copyright is retained by University of Iowa Hospitals and Clinics. Permission is not granted for placing on the internet.

Citation: Iowa Model Collaborative. (2017). Iowa model of evidence-based practice: Revisions and validation. Worldviews on
Evidence-Based Nursing, 14(3), 175-182. doi:10.1111/wvn.12223
In written material, please add the following statement:
Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright 2015. For permission to use or
reproduce, please contact the University of Iowa Hospitals and Clinics at 319-384-9098.
Please contact UIHCNursingResearchandEBP@uiowa.edu or 319-384-9098 with questions.

*note: This document was an email correspondence
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Appendix D: Liberty University IRB Approval Letter
February 3, 2020
Samantha Wilkins-Copeland
Kenneth Thompson
Re: IRB Application - IRB-FY19-20-39 PREVENTING POLYPHARMACY AMONGST THE
ELDERLY IN AN ACUTE CARE SETTING THROUGH THE INTEGRATION OF THE
START, STOPP, AND BEERS CRITERIA
Dear Samantha Wilkins-Copeland, Kenneth Thompson:
The Liberty University Institutional Review Board (IRB) has reviewed your application in
accordance with the Office for Human Research Protections (OHRP) and Food and Drug
Administration (FDA) regulations and finds your study does not classify as human subjects
research. This means you may begin your research with the data safeguarding methods
mentioned in your IRB application.
Decision: No Human Subjects Research
Explanation: Your study does not classify as human subjects research because:
(2) evidence-based practice projects are considered quality improvement activities, which are not
considered “research” according to 45 CFR 46.102(d).
Please note that this decision only applies to your current research application, and any
modifications to your protocol must be reported to the Liberty University IRB for verification of
continued non-human subjects research status. You may report these changes by completing a
modification submission through your Cayuse IRB account.
If you have any questions about this determination or need assistance in determining whether
possible modifications to your protocol would change your application's status, please email us
at irb@liberty.edu.
Sincerely,
G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
Research Ethics Office
*note: This document was an email correspondence
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Appendix E: Host Organization IRB Approval Letter

Mar 18, 2020
The project as described does not meet the criteria for Human Subject Research. No
additional IRB submission/review is necessary for you to proceed with this project. Please refer
to the attached IRB signed Determination (see PDF) for additional information.
Your project was assigned IRB Tracking Id # 22229. This tracking ID has been added to
the project documents attached.
This project was determined to be a QI project. The results may only be published as qi
and not as human subject research.
Please keep this email and all attached documents with the project files.
Contact the IRB if anything with this project changes OR if you have questions or
concerns.
Thanks,

Karen

Karen Coleman (Mimms) Mills, RN
Compliance Coordinator
IRB-HSR Board Member
Institutional Review Board-Health Sciences Research
*note: This document was an email correspondence
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Appendix G: Pre-Education Survey
Directions: Please complete this anonymous survey. Circle ONE answer per question.
1. What best describes your status within this organization? (please circle one)
Provider

Pharmacist

Manager

Nurse

Resident (subspecialty)___________________

Other (list)_____________
Intern (subspecialty)_____________

Attending (subspecialty)__________________
2. How familiar are you with utilizing the Screening Tool to Alert to Right Treatment
(START)? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Not at all familiar

3. How familiar are you with utilizing the Screening Tool of Older People's Prescriptions
(STOPP)? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Not at all familiar

4. How familiar are you with utilizing the Beers Criteria? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Not at all familiar
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Post-Education Survey
Directions: Please complete this anonymous survey. Circle ONE answer per question.
5. How familiar are you with utilizing the Screening Tool to Alert to Right Treatment
(START)? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Not at all familiar

6. How familiar are you with utilizing the Screening Tool of Older People's Prescriptions
(STOPP)? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Not at all familiar

7. How familiar are you with utilizing the Beers Criteria? (please circle one)
Very familiar

Somewhat familiar

Neutral

Not very familiar

Thank you for completing this survey. Contact me with any questions:
Samantha Wilkins-Copeland MSN-Ed, BS, RN-BC, DNP/FNP Student
swilkins23@liberty.edu

Not at all familiar
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Appendix H: DNP Scholarly Project Budget

Item
Printing
Editing
Statistics software
Total Cost

Cost in dollars
25
200
50
275
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Appendix J: START/STOPP Tool Permission Letter

Dear Ms Wilkins-Copeland,

Please see attached. Scroll to the end of the Word document to find the S/S rules.
STOPP/START criteria are in the public domain and as such may be used for any
academic or audit purpose.
Yours, DOM
Prof. Denis O’Mahony, MD, FRCPI, FRCP(UK)
Department of Medicine, University College Cork &
Department of Geriatric & Stroke Medicine,
Cork University Hospital,
Wilton, Cork, Ireland
*note: This document was an email correspondence
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Survey Question 1:
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Survey Question 1 Pre-Education:
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Survey Question 1 Post-Education:
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Survey Question 2:
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Survey Question 2 Pre-Education:

Survey Question 2 Post-Education:
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Survey Question 3:
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Survey Question 3 Pre-Education:

Survey Question 3 Post-Education:
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Pre-Education Data:
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Pre-Education Admission Data:

Pre-Education Discharge Data:
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Post-Education Data:
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Post-Education Admission Data:

Post-Education Discharge Data:
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